| アブストラクト | Background: Recent drug enforcement activities have possibly suggested the presence of some calcium channel blocker antihypertensives in association with cocaine. The seizure revealed the possibility that the two drugs might have been used together for some unknown reasons. Methods: Hence, this study aimed at investigating the nature and frequency of adverse drug reactions (ADRs) reported in association with the concomitant use of calcium channel blockers (CCBs) and cocaine, using data from the FDA Adverse Event Reporting System (FAERS). Results: After removing duplicate reports, a total of 67 cases involving concomitant use of cocaine and CCBs were analyzed and were stratified into three groups based on the CCB involved: verapamil (n = 19), diltiazem (n = 30), and amlodipine (n = 18). Logistic regression analysis identified "product use for unknown indication" (beta = 0.33) as the strongest predictor of fatal outcomes. Age revealed a modest negative association with fatal outcome (beta = -0.93, intercept = 4.07). Concomitant substance use was reported in over 84% of cases. Frequently co-used substances included opioids, benzodiazepines, antidepressants, antihistamines, and alcohol. Poly-drug use was most pronounced in the diltiazem group, which exhibited the highest burden of opioid and alcohol co-exposure. Conclusions: It is here suggested that clinicians should exercise caution when managing individuals who use cocaine, due to the potential for increased toxicity and lethality when CCBs are co-used, either as part of a prescribed treatment or if CCBs are present as adulterants in cocaine. |
|---|
| ジャーナル名 | Journal of clinical medicine |
|---|
| Pubmed追加日 | 2025/5/28 |
|---|
| 投稿者 | Chiappini, Stefania; Mosca, Alessio; Papanti Pelletier, Duccio G; Corkery, John M; Guirguis, Amira; Arillotta, Davide; Martinotti, Giovanni; Schifano, Fabrizio |
|---|
| 組織名 | Faculty of Medicine, Department of Psychiatry, UniCamillus University of Medical;Sciences, Via di S. Alessandro 8, 00131 Rome, Italy.;Department of Neurosciences, Imaging, and Clinical Sciences, University of;Chieti-Pescara, 66100 Chieti, Italy.;Cividale Community Mental Health Centre, ASUFC Mental Health Department, Friuli;Venezia Giulia, 33100 Udine, Italy.;Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,;University of Hertfordshire, Hertfordshire AL10 9AB, UK.;Pharmacy, Swansea University Medical School, Swansea University, Wales SA28PP,;UK.;Department of Pharmacology and Toxicology, University of Florence Medical School,;50134 Firenze, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40429456/ |
|---|
